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1. Introduction
Gingival overgrowth (GO) or gingival enlargement refers to important changes of gums aspect
and function. Even it seems an issue of little significance, health of gums is a prerequisite
condition for a psychological and physical comfort because severe GO affects speech, masti‐
cation, and nutrition, causes aesthetic concerns and increases susceptibility for periodontal
and systemic diseases. The treatment of severe cases needs gingivectomy that may be repeated
if is necessary.
At clinical endo-oral examination, GO is characterized by increased gums volume, swollen
and deepening of gingival sulcus. Thickening of soft tissues covering alveolar ridges is more
than 1 mm comprising both the mobile and attached gums. The degree of overgrowth can be
variable from the interdentally papilla to cover the entire tooth crown. Enlargement is painless,
slowly progressive and depends to a great extend on the oral hygiene [1-6].
Usually, GO is classified according the clinical appearance and the etiological factor. Histo‐
logical and cell molecular studies have uncovered some of the pathogenic pathways and
cellular alterations associated with GO but still remain unknown aspects.
In this chapter we describe recent insights into the pathogenic mechanisms of GO overgrowth
discussing in detail the role of epithelial-mesenchymal transition (EMT) in gingival fibrotic
diseases.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and eproduction in any medium, provided the original work is properly cited.
2. Terms definition, classification and risk factors for gingival overgrowth
Gingival overgrowth (GO), often named gingival hyperplasia or hypertrophy, is classified
according the clinical appearance and the etiological factors, if these are known. If clinical
examination displays rather an inflammatory aspect (gingivitis and periodontitis) the gums
are red, soft, shiny, and bleed easily. Inflammatory gingivitis is induced frequently by poor
dental hygiene resulting in bacterial plaque and causes reactive GO, named also focal reactive
GO, inflammatory hyperplasia or epulis. Generally, the epulides are pedunculated or sessile
lesions of gums; because this term, considered unsuitable, is clinico-topographical, without a
histological description of the lesion, nowadays the preferred term is gums reactive lesion [7,
8]. Smoking, systemic diseases (diabetes mellitus, HIV infection) determine also inflammatory
gums lesions.
Non inflamed gingival enlargement tends to have a darker red or purple color, is either firm
or soft, when bleeds easily. Determinative causes are extremely polymorphous: (i) subjects
with poor dental hygiene; (ii) specific hormonal states-puberty, pregnancy; (iii) nutritional
deficiency, such as scurvy; (iv) blood conditions, such as acute leukemia, lymphoma or aplastic
anemia; (v) genetic conditions – epulis or Neumann tumor; (vi) drug-induced GO (named also
fibrotic gingival hyperplasia) appeared after administration of some anticonvulsivants
(phenytoin), immunosupressants (cyclosporin A, CsA) and antihypertensive calcium channel
blockers (verapamil, diltiazem, nifedipine); (vii) systemic diseases such as sarcoidosis, Crohn
disease, acromegaly, primary amyloidosis or type I neurofibromatosis [6,9,10].
Gingival fibromatosis (GF) is the term frequently used for any GO when suspect a hereditary
pattern (hereditary gingival fibromatosis, HGF), as part of a more extensive syndrome (Table
1) or the etiologic factor remains unknown-idiopathic gingival fibromatosis (IGF). Specialty
literature is sometimes confuse or redundant regarding the relation between definition and
the etiological factors. For the beginning, we tried to present a brief synthesis of these defini‐
tions.
Hereditary gingival fibromatosis (HGF), previously known as gingival elephantiasis, idio‐
pathic gingival fibromatosis, hereditary gingival hyperplasia, non-bacterial plaque gingival
lesion, gingival gigantism or just hypertrophic gums [11,12] can be classified as follows:
i. Hereditary or isolated GF named also non-syndromic or type I GF seems to be
determined by the mutation of SOS1 (Sun of sevenless-1) gene on chromosome 2. For
the first time, this mutation was described in a large Brazilian family [13]. SOS1 is an
oncogene involved in cell growth. This mutation was designated GINGF1 (Mendelian
Inheritance in Man classification MIM135300) [10].
Recently a type 2 HGF, GINGF2 (MIM605544), was described in association to a mutation
mapped on chromosome 5 but the specific gene involved has not yet been identified [10,14-16].
The presence of teeth in alveoli seems to be a condition for hereditary GO development as it
disappears or reduces after tooth extraction. Some authors consider HGF an atypical pathology
of childhood because it is present mainly during the mixed dentition stage [11]. Another type
of HGF with family aggregation, GINGF3 (MIM 609955), a mutation mapped on chromosome
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2 but not to the SOS 1 gene in which clinical signs appear earlier during the primary dentition
stage was described by [17].
ii. Syndromic GF is associated with several clinical signs in some syndromes (Table 1).
In syndromic GF, gingival events are caused by chromosomal abnormalities (dupli‐
cations, deletions) of chromosomes 2p12-16 [18,19], 4q (MIM252500), 8 (MIM266270),
14q [20], 19p (MIM266200), 19q (MIM248500) and Xq [8,9,13,21-26].
Syndrome Clinical signs
Zimmerman-Laband Syndrome GF and facial deformability, changes of nose and ears, nail dystrophy,hypoplasia, epilepsy, hepato-splenomegaly, deafness, mental retardation
Rutherford Syndrome GF and corneal dystrophy, aggressive behavior, mental retardation
Jones Syndrome GF and progressive deafness, maxillary odontogenic cysts
Cross Syndrome Gingival hypertrophy and microphthalmia, mental retardation,hypopigmentation
Murray-Puretic-Drescher Syndrome GF and bone, cartilage, skin and muscle diseases
Ramon Syndrome GF and cherubism, hypertrichosis, mental retardation, convulsions, growthretardation, juvenile rheumatoid arthritis
Cowden Syndrome Localized GF with multiple hamartomas
Table 1. Syndromic gingival fibromatosis [adapted after 6,15,16,27]
Recently, in [28] is described a new syndrome that includes generalized thin hypoplastic
amelogenesis imperfecta found in a family with multiple consanguineous marriages, this type
having clinical and histological similarities with GINGF1 and GINGF3.
Genetic and syndromic fibromatosis are sometimes termed IGF [12,27,29-32].
Lacking specific immunohistochemical markers, the diagnosis of HGF is based exclusively on
clinical examination, patient medical history and family pedigree.
It was recommended to use the term „idiopathic fibromatosis” only for GF that doesn’t
incriminate genetic and hereditary causes mentioned above, in order to avoid these confusions
of classification [6,9].
GO incidence varies according the socioeconomic status and the risk factors involved being
reported a rate of 1/9000 adults; the most numerous GO are inflammatory or induced by drugs-
phenytoin increases gingival volume in 57% of cases, CsA in 30-46% and calcium channel
blockers in 10% [3,33,34]. HGF is the most rare type of GO and estimated to affect 1/750,000
people with the same incidence in both sexes [2,6,10,35,36].
Under the influence of such risk factors, clinical increase of gums volume is due to the
enlargement of both epithelial and connective tissue. Microscopically examination displays
the coexistence of tissue hypertrophy and cellular hyperplasia which imposed the generic term
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of GO [2]. Irrespective the risk factor, presence of bacterial plaque and hereditary predisposi‐
tion are constantly incriminated as etiological cofactors mainly for drug-induced GO [2]. To
sustain this association, it was revealed that patients with inflammatory GO before the onset
of treatment with CsA developed more severe forms of GO [37] and suggested that patients
carriers of a genetic polymorphism related to IL-1A expression often develop GO after CsA
treatment [38]; specialty literature reports cases of IGF or HGF associated with chronic or
aggressive periodontitis [39-41].
3. Histological aspects of gingival fibromatosis
Histological studies that we performed on samples of fibrotic gingival tissues revealed
common, non-specific aspects despite the numerous risk factors, generally characterized by
an increase of gums volume to which contribute both the epithelium (cellular hyperplasia) and
lamina propria (accumulation of extracellular matrix, ECM, and cells) (Figure 1). Various types
of GF are characterized by different incidence of pro-inflammatory cells.
Figure 1. General view of a sample with gingival overgrowth (trichrome staining, x100)
In drug-induced GO, connective tissue is more rich in pro-inflammatory cells than in HGF or
IGF. An exception is phenytoin-induced GO characterized mainly by fibrotic lesions unlike
CsA or nifedipine-induced GO which determine important inflammatory reactions [23,42-45].
Due to its clinical and histological features, phenytoin-induced GO is often included in the
category of fibromatous GO [11,15,23] which yield some confusions.
Histological changes of syndromic GO, HGF and phenytoin-induced GO are similar: epithelial
hyperplasia with hyperkeratosis and elongated papillae, thickening of collagen bundles,
increase of tissue differentiation and fluctuating number of fibroblasts (Figure 2a).
Enlargement and acanthosis of gingival epithelium with deep epithelial ridges was reported
[46, 47]. Epithelial hyperplasia results from acanthosis but appears only in the areas of chronic
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inflammation [46-48]. In many areas epithelial hyperkeratosis was observed [17,26,47,49].
Regarding the sulcular epithelium we noted many signs of considerable degeneration,
subpepithelial edema and extensive inflammatory cell infiltration (Figure 2b). Thick, densely
wrapped collagen bundles with scattered resident cells of connective tissue were observed in
lamina propria.
Figure 2. General view of syndromic GO: a) masticatory gingival mucosa; b) sulcular gingival mucosa (trichrome
staining, x100)
The incidence of fibroblast is disputed; some authors reported numerous fibroblasts
[16,31,45,50,51] while others claimed on the contrary a decreased number [17,41,43,52]. This
variable number of fibroblasts even within HGF pointed attention to the different molecular
mechanism underlying gingival fibrotic processes.
4. Pathogenic pathways of gingival overgrowth
Histological and cell molecular studies have uncovered some of the pathogenic pathways and
cellular alterations associated with GO but still remain unknown aspects.
Studies revealed that the same molecules and biological events are involved in inflammation,
wound repair and fibrosis. Theories and previous investigations on the morphology and
molecular mechanisms by which the fibrotic deposition occurs have been widely published.
Integrating these findings, Bartold and Narayanan state in [53] that fibrosis can evolve as a
response to the action of a single factor or of a combination of various factors such as: (i)
abnormal release of inflammatory mediators; synthesis of some molecules frees others and
their crosstalk could have synergic, cumulative or antagonist effects; (ii) persistence of
abnormal changes in the action of growth factors and cytokines; even the intensity of cell
response to this stimulation is not so great the long lasting effect is cumulative and increased;
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(iii) establishment of a pro-fibrotic cell phenotype; aberrant interaction of normal cell pheno‐
types with peptide mediators could induce the recruitment of abnormal cells.
These cell interactions determine the accumulation of gingival tissue through two main
pathogenic pathways: (i) excessive synthesis of ECM and (ii) decrease of its breakdown
[15,23,43,53-55]. Each of these pathways is initiated and sustained by growth factors, cytokines,
molecules involved in ECM breakdown, matrix metalloproteinases – MMP, and their tissue
inhibitors (TIMP) released by cellular elements that belongs both to the epithelium and
gingival chorion. Recently, epithelial to mesenchymal transition (EMT) has been proposed as
another pathogenic pathway promoting gingival fibrosis.
5. Role of epithelium in extracellular matrix accumulation — The
epithelial-mesenchymal transition
Development of fibrotic lesions is indirectly related to the presence and histophysiology of
epithelial cells. The interference of oral epithelial cells in ECM storage is sustained by the results
of many studies reporting epithelial morphological changes besides the accumulation of
connective tissue. In the same time, epithelial keratinocytes or inflammatory cells infiltrating
the epithelium synthesize several biomolecules (growth factors, cytokines, MMPs and TIMPs)
which alter collagen metabolism and ECM synthesis in the lamina propria. In a recent study,
Menga and coworkers in [56] showed an intense expression of type 1 collagen and TIMP-1 in
fibroblasts from mixed cultures of keratinocytes and fibroblasts obtained from patients with
GF, in parallel to an increased rough endoplasmic reticulum. The authors suggested that
keratinocytes play an important role in the pathogenesis of GF through increase of ECM
storage. The epithelium suffers acanthosis and hyperkeratosis, increases the number of
epithelial cells, and of many inflammatory cells infiltrating its deep layers. The increase of
keratinocytes number determines not only the epithelial enlargement mainly in the spindle
layer but also the appearance of many epithelial ridges ascending deep in the lamina propria.
These epithelial ridges often branch and adhere one to another (Figure 1, and 2a, b).
These findings are constantly accompanied by the increase of keratinocyte mitotic activity
proved by Ki-67 or PCNA immunostaining in [45,57-60]. In a recent study, using immunohis‐
tochemistry, [61] reported that Mcm-2 and Mcm-5 (members of minichromosome maintenance
protein family), considered a novel class of proliferation markers, and geminin, also a prolif‐
eration marker according to [62], showed various expression in samples from three different
families with GF. No differences between the expression of apoptotic markers Bcl-2 and Bax
were observed among the group. Thus the authors concluded that an important heterogeneity
of gingival fibrosis occurs. Epithelial cells proliferation is stimulated by pro-inflammatory
cytokines and growth factors, such as KGF (Keratinocyte Growth Factor) or EGF (Epidermal
Growth Factor). EGF and its receptors (EGfr) are positively correlated with the proliferative
potential of the cells from rete pegs [63,64]. In a previous study, we observed that epithelial
cells have an increased mitotic index in cases of GF highly infiltrated with inflammatory cells
(Figure 3) (unpublished data).
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Epithelial proliferation seems to have at least two functions in GO. First it ensure a continuous
regeneration of keratinocytes, the regenerative capacity of the epithelium being compulsory
when continuous desquamation of the superficial cells prevents bacterial colonization of the
mucosa; second, epithelial proliferation could contribute to fibrosis by maintaining a cell pool
to replace those cells involved in EMT and transformed in fibroblasts.
Figure 3. Gingival fibrosis. Increased number of Ki-67 positive cells in the basal epithelial layer (IHC, x200)
5.1. Concept of epithelial-mesenchymal transition
Epithelial-mesenchymal transition (EMT) is a concept first defined “epithelial–mesenchymal
transformation” by G. Greenburg and E. Hay to characterize the conversion of epithelial cells
to mesenchyme (EMT) and vice versa (mesenchymal-epithelial transition, MET) during chick
embryonic development. This well-defined concept refers to a form of inherent plasticity of
the epithelial phenotype that occurs normally in the developmental process. During EMT cells
undergo a switch from a uniform, polarized epithelial phenotype to a motile mesenchymal
phenotype. Current interest in this process stems from its importance in embryonic develop‐
ment and involvement in several pathologies (wound healing, fibrosis, cancer progression and
metastasis) and has been extensively reviewed over the last 10 years in [65-78]. The conversion
of an epithelial cell to a mesenchymal cell is critical to metazoan embryogenesis and a defining
structural feature of organ development, and follows a common and conserved program with
hallmarks [69,77]. As Lamouille and coworkers suggest in [77] it also has some variation which
depend on the cell type, tissue environment and signals that activate the EMT program. During
EMT, epithelial cell–cell and cell–ECM interactions are weakened and epithelial cells become
able to trans-differentiate into fibrogenic fibroblast-like cells [68]. Turning an epithelial cell
into a mesenchymal cell requires alterations in morphology, cellular architecture, adhesion,
and migration capacity [69]. Loss of epithelial apical-basal polarity, acquisition of a front-rear
polarity and motility result from the disappearance of cell adhesion molecules, reorganization
of cytoskeleton and changes in cell shape [70]. In many cases cells gain an increased ability to
break ECM proteins, acquire resistance to senescence and apoptosis [73].
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Research in this field revealed that cellular events of EMT occurs in three distinct biological
settings with different functional consequences: (i) type 1 EMT acts during implantation,
embryogenesis and organ development when can generate mesenchymal cells (primary
mesenchyme) and then secondary epithelia after the mesenchyme undergoes a reverse MET;
(ii) type 2 EMT as a source of fibroblasts and other related cells involved in tissue regeneration
and organ fibrosis in response to persistent inflammation; (iii) type 3 EMT occurs in neoplastic
cells that have undergone genetic and epigenetic changes, notably of oncogenes and tumor
suppressor genes, and contributes to cancer progression and metastasis [72,76,79]. A main
distinction between the first two types of EMT is that type 1 EMT produces mesenchymal cells,
whereas type 2 EMT results in fibroblasts in mature tissues. But other than the fact that
mesenchymal cells have a shape similar to fibroblasts and, like fibroblasts, express fibronectin
and fibrilar collagens, there is no evidence that fibroblasts originate in primitive mesenchymal
cells [78].
EMT induction. Successful EMT depends upon a combination of growth factors and cytokines
associated with the proteolytic digestion of the epithelial basement membranes (BM) under
the action of MMPs. Local expression of TGF-β, EGF, IGF-II or FGF-2 facilitates EMT by binding
membrane receptors with kinase activity [65]. The effect of TGF-β on EMT induction depends
on β1-integrin transduction, Smad-dependent transcription, Smad-independent p38MAP
kinase activation and Rho-like GTPase-mediated signaling [80,81]. IGF-II also facilitates the
intracellular degradation of E-cadherin [82], while FGF-2 and TGF-β are required for the
expression of MMP-2 and MMP-9 to assist in BM breakdown [83]. Indeed, decrease of type IV
collagen from the BM was associated with increased expression of MMP-2 and MMP-9 during
human pathologies involving EMT [54,84]. Loss of BM integrity is essential for the increased
interactions between epithelial and connective tissue layers that contribute to fibrosis. Several
lines of evidence indicate that TGF-β signaling is causally linked with EMT, plays an important
role in regulating epithelial plasticity and is one of the most significant lines of communication
between stroma and epithelium in different organ fibrosis (renal, cardiac, pulmonary, and
hepatic) [81].
Consequent cell and molecular events are engaged to initiate EMT and enable it to complete:
i) activation of transcription factors; ii) expression of cell surface specific proteins; iii) reor‐
ganization and expression of cytoskeletal proteins; iv) synthesis of ECM-degrading enzymes.
In many cases, these factors are used as biomarkers to prove cell passage from one phenotype
to the other and EMT involvement in tissue remodeling (Figure 4).
Transcriptional regulation of EMT. EMT involves changes in gene expression that induce the loss
of proteins associated with the epithelial phenotype and increased expression of proteins
associated with a mesenchymal and migratory cell phenotype with concomitant alterations in
cytoskeletal organization, cell adhesion and production of ECM [72]. Cellular plasticity that is
the switch of epithelial to mesenchymal features is achieved through a well orchestrated
program that involves the action of three families of transcription factors: Snail, ZEB (zinc-
finger E-box-binding) and bHLH (basic helix-loop-helix). Expression of these factors is induced
in response to TGF-β through different mechanisms and their function is finely regulated at
transcriptional, translational and post-translational levels [77].
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Snail family. Three Snail proteins have been identified in vertebrates: Snail 1 (Snail), Snail
2 (Slug) and Snail 3. They function as transcription repressors and their activity depend on
the C-terminal zinc finger domain and the N-terminal SNAG domain [77].  Snail  expres‐
sion is induced in response to various growth factors. In cells that undergo TGF-β induced
EMT  Snail  expression  is  mediated  by  Smad2/3  that  form  complexes  with  Smad4  and
activates transcription by binding to Snail promoter [85]. Expression of Snails suppresses a
spectrum of genes involved in maintaining the epithelial structure and function (Table 2)
and enhances the expression of genes encoding vimentin and fibronectin leading to a full
phenotype.
ZEB family. Two ZEB proteins have been identified in vertebrates, ZEB1 and ZEB2, which have
two zinc-finger clusters at each end who mediates the interaction with DNA regulatory
sequences. TGF-β induces the expression of ZEB proteins through an indirect mechanism
mediated in part by Ets-1 and then ZEBs interact with Smad3 and repress the expression of
epithelial marker genes (E-cadherin, claudins, ZO-3, plakophilin-2) and induce the expression
of mesenchymal proteins (vimentin, N-cadherin, MMP-2) [86-88].
Helix-loop-helix family. HLH is a large family of transcription factors divided into seven classes
based on their tissue distribution, dimerization ability and DNA-binding specificity [89]. The
structure of HLH includes two parallel α-helices linked by a loop required for dimerization.
E12, E47, Twist and Ids are involved in EMT. E12, E47 and Twist are able of DNA binding
while Ids proteins are unable and act as dominant negative inhibitors [90]. Ectopic expression
of E12 and E47 represses E-cadherin, plakoglobin or desmoplakin expression and induces
mesenchymal markers, such as vimentin, fibronectin, N-cadherin or α5-integrin, and promotes
migration and invasion [90]. Expression of Twist decreases E-cadherin, claudin-7 and occludin
expression, increases that of N-cadherin and vimentin, and enhances migration and invasion
[91]. Ids expression is repressed in response to TGF-β [92,93].
EMT proteome. Commonly used molecular markers of EMT could be grouped as follows: (i)
decrease the amount of proteins associated with the epithelial phenotype; ii) abundance of
some proteins; (iii) increased activity of selected proteins (Rho, GSK-3β); (iv) accumulation of
proteins within the nucleus [69]. Table 2 listed common members of EMT proteome.
Figure 4. EMT is a functional transition from polarized epithelial cells into mobile cells able to secrete extracellular
compounds (adapted after [72])
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Delaminating of epithelia to facilitate movement is dependent on cell context and growth factor
signaling and is accompanied by a decrease of apoptosis and mitosis [65].
In fibrotic diseases, TGF-β/Smad/Snail is a key signaling pathway [72,81]. Subsequently E-
cadherin, cytokeratin, claudin and occludin are repressed, while FSP1 (fibroblast-specific
protein-1), vimentin, fibronectin, Rho and MMP are increased [78].
According to [96] EMT represents the main source of fibroblasts in fibrotic pathology of
connective tissues.
Generally, researches focused on few EMT markers and for this reason are not comprehensive.
We specify that most information about the presence of EMT markers is indicated by the
presence of proteins in epithelia and not only in fibroblasts, and as an example we’ll discuss
later the expression of FSP1.
Proteins that decrease in abundance
Name EMT Type
E-cadherin
Cytokeratins
Occludin
Claudins
ZO-1
Collagen IV
Laminin 1
1,2,3
1,2,3
1,2,3
1,2,3
1,2,3
1,2,3
1,2,3
Proteins that increase in abundance
N-cadherin
Vimentin
α-SMA
Fibronectin
FSP-1
Snail, Slug
ZEB
Twist, E12/E47
Ets-1
MMP-2, MMP-9
αvβ6 Integrin
1,2
1,2
2,3
1,2
1,2,3
1,2,3
1,2,3
1,2,3
1,2,3
2,3
1,3
Proteins that accumulate in the nucleus
β-catenin
Smad2/3
NF-κβ
Snail, Slug
Twist
LEF-1
Ets-1
ZEB
1,2,3
1,2,3
2,3
1,2,3
1,2,3
1,2,3
1,2,3
1,2,3
Table 2. Epithelial-mesenchymal transition proteome (modified after [69,78])
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FSP1, also known as S100A4 is one of the most interesting proteins identified in the EMT
proteome [94]. This is a fibroblast-specific protein member of the S100 superfamily of cyto‐
plasmic, calcium-binding proteins. S100 members have been implicated in calcium signal
transduction, cytoskeletal membrane interactions, microtubule dynamics, p53-mediated cell
cycle regulation, cellular growth and differentiation. Because the precise function of FSP1 is
not entirely clear, its interaction with cytoskeletal moieties suggest that FSP1 protein may be
associated with mesenchymal cell shape to enable motility and its expression indicates the
presence of a molecular program determining the fibroblast phenotype in many organ fibrosis
(kidney, liver, heart, brain, lungs) [72,94,95]. FSP1 is a specific marker not only for fibroblasts
but also for endothelial cells undergoing endothelial-mesenchymal transition (EndMT) [78,96].
5.2. Epithelial-mesenchymal transition in gingival overgrowth
The process of EMT is involved in the normal development and several pathologies of oral
cavity. In oral tissues, type 1 EMT is associated to palate and root development, type 2 EMT
could play a contributory role in GF and oral submucous fibrosis and type 3 EMT is responsible
for progression, invasion and poor prognosis of oral squamous cell carcinoma [76,97].
Fibrosis which occurs in many epithelial organs (kidney, liver, lung, heart, intestine) begins as
a part of a repair event, that normally generate fibroblasts by EMT mechanism in order to
reconstruct tissues following inflammatory injury. It seems that in gingival fibrosis as in other
organs, the main trigger for type 2 EMT is the cytokine bath released in response to persistent
inflammation [78,98]. Inflammatory injury results in the recruitment of a diverse array of cells
(mainly resident fibroblasts and macrophages) that release growth factors (TGF-β, PDGF, EGF,
FGF-2) and MMPs, especially MMP2, MMP3 and MMP 9 [72]. Under the influence of these
factors and others chemoatractants [83] the delaminated epithelial cells migrate towards the
disruptions of the BM. In EMT a discontinuous BM accompanied by a decreased expression
of collagen IV and laminin was reported [54]. First the epithelial cells loss the polarity, cell
adhesion molecules are disrupted and cell-cell junctions disappears. The intermediate filament
profile change from cytokeratins to vimentin, the F-actin rearranges to a mesenchymal shape
and some cells begin to express α-smooth muscle actin (α-sma) [83]. Epithelial cells undergoing
EMT are specifically labeled in vitro and also in vivo [65,99,100] by FSP1, collagen type 1 and
α-sma [78,94].
Recently, was provided data about EMT origin of gingival fibroblasts in drug-induced GO.
The authors reported that mesenchymal cells from the lamina propria raised after phenotypic
changes of some cells from the basal and parabasal epithelial layers [54,60, 101]. These cells
had a diminished expression of E-cadherin compared to others; meanwhile the majority of
keratinocytes expressed FSP1. Besides phenytoin-induced GO, we reported similarly results
in a case of syndromic GO (Figure 5.) [47].
As we mentioned before, the main growth factor involved in EMT is TGF-β1 that triggers
activation of the transcription factors able to repress the expression of epithelial markers, for
example E-cadherin.
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Figure 6. Idiopathic GO: a. Immunostaining for E-cadherin, x400; b. Immunostaining for TGF-β1, x200. c. Independent
epithelial cells very close to the basal lamina, x400; d. FSP1 positive cells in the basal epithelium and the superficial
connective tissue of the chorionic papilla, x 400.
Immunohistochemical studies that we performed on fibrotic GO samples revealed a dimin‐
ished expression of E-cadherin in the basal epithelial layer in proximity of the BM suggesting
that these cells undergo EMT while the immune reaction for TGF-β1 revealed many positive
cells deep in the epithelium, mainly in the epithelial rete ridges [46,101]. A careful examination
Figure 5. Syndromic GO. FSP1-positive reaction not only in fibroblasts but also in many keratinocytes, probably those
that undergone EMT (IHC, a.x 100; b. x 400).
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of these areas revealed independent epithelial cells detached from their neighbors, some of
them extremely close to the basal lamina. In the lamina propria, adjacent to the BM we observed
numerous intense FSP1 positive cells (Figure 6) (unpublished data).
The same results we reported in cases of phenytoin induced GO. Regarding the expres‐
sion  of  FSP1  we  observed  an  increased  number  of  S100A4  positive  cells  both  in  the
epithelium and lamina propria. At higher magnification we detected these FSP1 positive
cells mainly in the basal epithelial layer nearby the disrupting BM and in the connective
tissue close to the epithelium [101].  Tissues with phenytoin-induced GO showed signifi‐
cant  reduction  of  E-cadherin  expression  in  the  epithelium  compared  with  tissues  from
subjects  without  overgrowth where E-cadherin had a  constant  presence in  the  adherent
junctions between keratinocytes. For the same samples we performed the assessment of the
transcription factors Smad3 and Snail. We found an up-regulation in cells from profound
epithelial layers. Often these positive cells were round or elongated, surrounded by a clear
halo and we presumed that as a prove for lost of adhesion and the possibility to cross the
disrupting BM to the connective tissue (Figure 7). Endothelial cells were also positive for
these factors, especially for Smad3.
Overexpression of Snail, able to represses E-cadherin expression, and of MMP2 and MMP9
able to digest proteins from BM in the epithelium are downstream events of TGF-β1 biological
effects [60, 102]. Experimental data proved that supplementation of epithelial cell cultures with
TGF-β1 leads to loss of cell-cell adhesion through inhibition of E-cadherin gene expression and
decrease of adherent junctions, tight junctions and desmosomes [72,102,103].
5.3. Connective tissue growth factor and the epithelial-mesechymal transition
As we mentioned before, besides TGF-β1 other growth factors could be involved in EMT such
as IGF-II, EGF, FGF-2 and recently CTGF [104].
Figure 7. Phenytoin-induced GO. Expression of the transcription factors Smad 3 (a, x100) and Snail1 (b, x100).
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TGF-β1 acts as a strong pro-fibrilogenetic factor through several mechanisms: (i) direct
stimulation of collagen synthesis after the increase of number of highly collagen synthesizing
fibroblasts through EMT; (ii) initiation of CTGF control on collagen synthesis [105]. Kantarci
and coworkers in [104] showed a direct relation between the incidence of FSP1 positive cells
and CTGF expression in drug-induced GO.
CTGF/CCN2 is a member of the CCN family whose members contain conserved cysteine-rich
domains and have various biological activities, being important to stimulate proliferation of
diverse cell types and to promote fibrosis [105]. CTGF/CCN2 is highly expressed in a wide
variety of fibrotic lesions and was already demonstrated that CTGF levels are highest in
gingival tissues from phenytoin induced lesions, intermediate in nifedipine-induced lesions,
and nearly absent in CsA-induced overgrowth [44,106]. CTGF/CCN2 expression in connective
tissue fibroblasts was positively related with the degree of fibrosis because CTGF is able to
stimulate fibroblast proliferation and ECM synthesis.
We performed immunohistochemical studies to reveal the pattern of CTGF expression in
various types of GO and we noted a constant intense CTGF positive reaction in all cases. We
observed strong positivity in the epithelium and lamina propria not only in fibroblasts but also
in endothelial and pro-inflammatory cells (Figure 8).
In  phenytoin-induced GO and IGF,  the  most  fibrotic  types  of  GO,  CTGF/CCN2 content
was  significantly  higher  compared  to  GO  induced  by  other  drugs  (nifedipine,  amlodi‐
pine) and controls. Similar results were reported by Kantarci and coworkers in [44] who
revealed that  CTGF/CCN levels were elevated in phenytoin-induced fibrotic  lesions and
HGF, the highest CTGF positive reaction being observed in the basal epithelial layer and
the  superficial  connective  tissue.  Because  the  presence  of  CTGF  in  the  epithelium  is
intriguing, they performed in situ hybridization to identify cells that express CTGF mRNA
and confirmed the presence of a high amount of CTGF in the basal epithelial layer [44].
In the connective tissue, CTGF promotes local fibrosis but its presence in the epithelium
could have a  distinct  significance as  was mentioned for  the  uterine  tissue where CTGF
stimulates cell proliferation. The authors suggest that CTGF could also stimulate gingival
cells proliferation, mesenchymal cells and also keratinocytes from the basal layer reveal‐
ing an increased mitotic index in GO [44].
6. Role of mesenchymal cells in gingival overgrowth
The main cells of gingival connective tissue incriminated for increased collagen synthesis are
logically the fibroblasts. Gingival fibroblasts are involved in ECM homeostasis through a dual
effect. On the one hand, they are responsible for collagen synthesis and, on the other hand, by
a process of phagocytosis, it performs ECM breakdown.
Under normal circumstances, but especially in organ fibrosis, fibroblasts show different
origins. For example, in kidney fibrosis, the trans-differentiation of epithelial cells through
EMT is responsible for 36% of fibroblasts, 14-15% originated in bone marrow stem cells-namely
fibrocytes [99] and the rest from local fibroblast proliferation. [65]
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Kisseleva and Brenner showed in [99] that there are differences between the expression of
several markers in fibrocytes and fibroblasts. The fibrocytes are cells involved in skin, kidney,
liver and lung fibrosis. They have dual phenotypic features between fibroblasts and lympho‐
cytes, and are defined as CD45+cells able to synthesize collagen with bone marrow origin,
where they represents ≤1% of the cell population. Tissue injuries increase their number and
after proliferation spread through blood into the damaged tissue where their proportion varies
in relation to the tissue (5%-25%). [107,108]
In  vitro  the  fibrocytes  can  differentiate  into  α-sma-positive  myofibroblasts  following
stimulation by TGF-β1.  The authors suggest that the role of these cells  is  not limited to
tissue fibrilogenesis  but  to  fulfill  a  role  of  intermediary in the biosignaling between the
immune and fibrogenetic cells. This observation is based on the fact that fibrocytes express
lymphoid  markers  (CD45,  MHC  II,  MHC  I),  myeloid  markers  and  adhesion  molecules
(CD54, ICAM-1) but also fibroblast markers (Thy-1, α-1 collagen). In addition, fibrocytes
Figure 8. Immunostaining for CTGF in various samples of gingival fibromatosis: a, b. Idiopathic GF, x200, c. Pheny‐
toin-induced GF, x100; d. Reactive GF, x200.
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secrete growth factors and cytokines, for example TGF-β1, that stimulate the local deposi‐
tion of ECM constituents. [109]
The second type of fibroblast-like cells derived still from bone marrow is represented by
fibroblasts which in contrast to fibrocytes do not express myelo-monocytic markers and
hyperexpress α-sma in vitro [110]. These are the main cells responsible for lung fibrosis.
Morphologically in fibrotic GO were described two populations of fibroblasts: one with little
cytoplasm, considered inactive, and the other, well represented, with abundant cytoplasm,
endoplasmic reticulum and Golgi apparatus-the active form. [29,111]
Kantarci and coworkers reported a reduction of fibroblasts apoptosis and at the same time an
increased fibroblasts proliferation regardless of the inflammatory infiltration in phenytoin-
induced GO and HGF which may explain the increased fibrosis. [45]
Through an autocrine signaling TGF-β1 seems to be the stimulus for increased collagen
synthesis in fibroblasts. Hakkinen and Csiszar in [112] advanced the hypothesis that in GF the
onset of overgrowth along with dental eruption can be placed either on account of the
differentiation of abnormal phenotype fibroblasts or following their activation by pro-
inflammatory cells or by mechanical trauma of eruption.
Recently there have been proposed two ways of stimulating fibroblasts proliferation either the
pathway induced by increased FAS (fatty acid synthase) expression [112,113] or by increased
expression of c-myc (a nuclear proto-oncogene) which hyperexpression is associated with
disturbances of cell proliferation. [114] Conflicting results regarding the proliferative activity
of fibroblasts in GF can be explained either by the genetic heterogeneity of the pathology itself
or by the small number of cases studied. [112]
Cells that undergo EMT reorganize their actin cytoskeleton in order to facilitate formation of
membrane projections that include sheet-like membrane protrusions or lamellipodia and
spike-like extensions or filopodia that enable cells to directional motility. [115] Finally, the
result of both EMT and EndMT is the myofibroblast, a mobile cell rich in actin stress fibers that
expresses α-sma. These processes have been named EMyt and EndMyt. [77,116,117]. The
mesenchymal phenotype resulting after EndMT is characterized by the acquisition of mesen‐
chymal markers, such as α-sma and N-cadherin and the complementary loss of endothelial
markers, such as CD31/Pecam-1 and VE-cadherin. [117] The mechanism of EndMT was
discovered in the process of heart-development but actually it had been implicated in a wide
variety of pathological conditions like several organs fibrosis and as well as in cancer. [98]
There is not a consensus regarding the fact that myofibroblasts of fibrotic tissue occur exclu‐
sively as a result of EMT, these cells having a very heterogeneous origin. In tissue injury the
local fibroblasts become activated by local cytokines released from inflammatory and resident
cells or by the change of the mechanical microenvironment. These cells become first proto‐
myofibroblasts – cells acquiring contractile stress fibers composed of cytoplasmic actin.
[118,119] In vivo such a protomyofibroblast became a differentiated myofibroblast by de novo
expression of α-sma, used for this reason as a molecular marker. [119]
Since  only  certain  subpopulations  of  myofibroblasts,  previously  called  activated  fibro‐
blasts, express α-sma [120,121] it has advanced the hypothesis that actin of smooth muscle
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could actually label the cells detached from the blood vessel walls as a response to local
injury. [122,123] At least three local events are needed to generate α-sma–positive differen‐
tiated  myofibroblasts:  (i).  The  accumulation  of  biologically  active  TGF-β1,  the  main
promoter  of  fibroblasts  differentiation  into  myofibroblasts  and  trigger  of  EMT;  (ii)  The
presence of  specialized ECM proteins,  like  the ED-A splice  variant  of  fibronectin.  Some
authors argue that in the presence of the granulation tissue fibroblasts gain progressively
features of myofibroblasts including α-sma expression [118,124] and (iii) High extracellu‐
lar stress raised from the mechanical properties of ECM and cell  remodeling activity. In
addition, in [119] have been suggested that bone marrow derived circulating cells known
as fibrocytes represent an alternative source of myofibroblasts in skin wound healing or
organ fibrosis. There are few reports in the literature referring to the evidence of myofibro‐
blasts  in reactive focal  GO, HGF and drug induced gingival  hyperplasia.  [25,47,126,127]
Schor and coworkers reported in [128] that the only tissues that do not develop post lesion
scars are embryonic and gingival tissues. This special reactivity was due to the fact that
gingival  fibroblasts  and  skin  activates  TGFβ1  by  different  signaling  pathways.  [129]
Following the experiments authors suggested that the lack of scars in gingival mucosa is
due to the fact that mechanical stress, a normal condition for functional periodontal tissues
and remodeling processes is translated into fibroblast proliferation, production of TGF-β1
and CTGF, but not in activating genes responsible for α-sma synthesis.
7. Conclusions and perspectives
EMT is a dynamic physio-pathological event that depends upon a fine crosstalk between
signaling pathways. Understanding the molecular mechanisms involved in EMT may reveal
new biological targets for an effective therapeutic control of fibrosis in syndromic and IGF.
Further studies are needed regarding the expression of genes that control the synthesis of ECM
under the particularities of structure and function of oral mucosa which normally is constantly
remodeled and, on the other hand, is in a continuous state of inflammation due to the contact
with different external agents. In this respect, special attention should be paid to factors that
govern the relationship between innate immunity and EMT.
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